The survival rates were not significantly changed in patients with high or low expression of MCM2 or MCM10 with MYCN-amplified neuroblastoma, suggesting that MYCN amplification is more dominant than MCM expression in determining poor prognosis in this patient subgroup (Figure S5). Here, MYCN is linked to neuroblastoma.